Search

Catherine A Bitler

from Menlo Park, CA
Age ~65

Catherine Bitler Phones & Addresses

  • 444 University Dr, Menlo Park, CA 94025 (650) 804-2384
  • San Clemente, CA
  • Seaside, CA
  • Escondido, CA
  • Redwood City, CA
  • Fremont, CA
  • Valley Center, CA
  • Camarillo, CA
  • Orange, CA
  • Monterey, CA
  • San Mateo, CA
  • San Diego, CA
  • 444 University Dr, Menlo Park, CA 94025 (650) 799-4797

Work

Company: Ecco biotech 2010 Position: Principal

Education

Degree: Postdoctoral School / High School: Stanford University Specialities: Neuroscience

Skills

Biotechnology • Lifesciences • Molecular Biology • Cell Biology • Strategic Partnerships • Biochemistry • Cell Culture • Product Development • Cross-functional Team Leadership

Emails

k***r@cfl.rr.com

Industries

Biotechnology

Resumes

Resumes

Catherine Bitler Photo 1

Ecco Biotech, Principal

View page
Position:
Principal at Ecco Biotech, Director at Organic Pet Nutrition
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
Ecco Biotech since 2010
Principal

Organic Pet Nutrition since 2008
Director

CreAgri Inc 2002 - 2010
V.P. Research & Development

Galileo Pharmaceutical 2000 - 2001
Director Cell & Molecular Biology

Neurex Corp 1994 - 2000
Director Cell Biology
Education:
Stanford University
Postdoctoral, Neuroscience
University of California, Los Angeles
PhD, Biological Chemistry
University of Southern California
BS, Psychobiology
Skills:
Biotechnology
Lifesciences
Molecular Biology
Cell Biology
Strategic Partnerships
Biochemistry
Cell Culture
Product Development
Cross-functional Team Leadership

Business Records

Name / Title
Company / Classification
Phones & Addresses
Catherine Bitler
Principal
Organic Pet Nutrition
Ret Misc Merchandise
444 University Dr, Menlo Park, CA 94025

Publications

Us Patents

Method For Selecting Compounds For Treating Ischemia-Related Cellular Damage

View page
US Patent:
6379882, Apr 30, 2002
Filed:
Sep 10, 1999
Appl. No.:
09/393137
Inventors:
Catherine M. Bitler - Menlo Park CA
Anke Meyer-Franke - Menlo Park CA
Paul Wood - Menlo Park CA
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C12Q 100
US Classification:
435 4, 435 6, 435 78, 514 3, 514 12, 514 13, 514 14, 514 21, 514 29, 514 35, 514 36, 514 37, 514 38, 514 46, 514 49, 530399
Abstract:
A method of screening for and treating subjects with a therapeutically effective amount of a compound that is effective in reducing cellular damage related to an ischemic condition, such as stroke or glaucoma. Test compounds are selected and therapeutically effective amount determined based on the relative efficacy of test compounds in preventing cell death in primary cultures of excitable cells, such as retinal ganglion cells, in vitro.

Bis-Benzimidazole Compounds And Analogs Thereof For Inhibiting Cell Death

View page
US Patent:
6541486, Apr 1, 2003
Filed:
Jun 2, 2000
Appl. No.:
09/587043
Inventors:
Catherine M. Bitler - Menlo Park CA
Paul L. Wood - Morgan Hill CA
Duran T. Anstine - Nampa ID
Anke Meyer-Franke - Menlo Park CA
Qi Zhao - Fremont CA
Mohamed A. Khan - Sunnyvale CA
Assignee:
Elan Pharma International Ltd. - Dublin
International Classification:
A61K 314184
US Classification:
514303, 514394, 546118, 5483057
Abstract:
Compounds, pharmaceutical compositions, and methods of use are described which are effective in inhibiting cell death, particularly apoptotic cell death. The compositions may be used for prevention and treatment of injuries associated with cell death, including ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation.

Methods For Selecting Compounds For Treating Ischemia-Related Cellular Damage

View page
US Patent:
20020102597, Aug 1, 2002
Filed:
Feb 12, 2002
Appl. No.:
10/074964
Inventors:
Catherine Bitler - Menlo Park CA, US
Anke Meyer-Franke - Menlo Park CA, US
Paul Wood - Menlo Park CA, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
A method of screening for and treating subjects with a therapeutically effective amount of a compound that is effective in reducing cellular damage related to an ischemic condition, such as stroke or glaucoma. Test compounds are selected and therapeutically effective amount determined based on the relative efficacy of test compounds in preventing cell death in primary cultures of excitable cells, such as retinal ganglion cells, in vitro.

Compositions For Treating Ischemia-Related Neuronal Damage

View page
US Patent:
20040072862, Apr 15, 2004
Filed:
Jan 29, 2003
Appl. No.:
10/354793
Inventors:
Catherine Bitler - Menlo Park CA, US
Paul Wood - Belmont CA, US
D. Anstine - Boise ID, US
Anke Meyer-Franke - Menlo Park CA, US
Qi Zhao - North Andover MA, US
Mohamed Khan - Mogan Hill CA, US
International Classification:
A61K031/4745
A61K031/4184
US Classification:
514/303000, 514/394000
Abstract:
Compounds, pharmaceutical compositions, and methods of use are described which are effective in inhibiting cell death, particularly apoptotic cell death. The compositions may be used for prevention and treatment of injuries associated with cell death, including ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation.

Vegetation Water Composition For Treatment Of Inflammatory Skin Conditions

View page
US Patent:
20070020350, Jan 25, 2007
Filed:
Jul 19, 2005
Appl. No.:
11/185246
Inventors:
Fujio Numano - Tokyo, JP
Roberto Crea - San Mateo CA, US
Tokuko Wiedemann - El Cerrito CA, US
Catherine Bitler - Menlo Park CA, US
International Classification:
A61K 36/63
US Classification:
424769000
Abstract:
Compositions obtained from vegetation water from olives and methods for treating patients suffering from an inflammatory skin disease with the compositions are described. Included are hydroxytyrosol rich compounds obtained from olive vegetation water.

Olive Compositions And Methods For Treating Inflammatory Conditions

View page
US Patent:
20080300198, Dec 4, 2008
Filed:
Aug 9, 2005
Appl. No.:
11/659861
Inventors:
Kathleen Matt - Gilbert AZ, US
Catherine M. Bitler - Menlo Park CA, US
International Classification:
A61K 31/7048
A61P 29/00
US Classification:
514 27
Abstract:
A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker.

Olive Compositions And Methods For Treating Inflammatory Conditions

View page
US Patent:
20110257117, Oct 20, 2011
Filed:
Jun 8, 2011
Appl. No.:
13/156275
Inventors:
Kathleen Matt - Gilbert AZ, US
Catherine M. Bitler - Menlo Park CA, US
Roberto Crea - San Mateo CA, US
International Classification:
A61K 31/7028
A61P 19/02
A61P 9/00
A61K 31/05
US Classification:
514 27, 514731
Abstract:
A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker.

Bax .Omega. Protein And Methods

View page
US Patent:
61404845, Oct 31, 2000
Filed:
Mar 10, 1998
Appl. No.:
9/037742
Inventors:
Catherine Mastroni Bitler - Menlo Park CA
Stephen Scott Bowersox - Menlo Park CA
Roberto Crea - San Mateo CA
Susan Dunham Demo - San Francisco CA
William A. Horne - San Diego CA
Mei Zhou - Palo Alto CA
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07H 2102
US Classification:
536 231
Abstract:
Bax-. omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-. omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-. omega. to other proteins involved in apoptosis.
Catherine A Bitler from Menlo Park, CA, age ~65 Get Report